Search results for "610"

showing 10 items of 1353 documents

Minimal Reporting Standards for Active Middle Ear Hearing Implants.

2017

There is currently no standardized method for reporting audiological, surgical and subjective outcome measures in clinical trials with active middle ear implants (AMEIs). It is often difficult to compare studies due to data incompatibility and to perform meta-analyses across different centres is almost impossible. A committee of ENT and audiological experts from Germany, Austria and Switzerland decided to address this issue by developing new minimal standards for reporting the outcomes of AMEI clinical trials. The consensus presented here aims to provide a recommendation to enable better inter-study comparability.

medicine.medical_specialtyConsensusPhysiologyHearing lossHearing Loss Sensorineural610 Medicine & healthAudiology03 medical and health sciencesSpeech and Hearing0302 clinical medicineHearing AidsHearingGermanyOutcome Assessment Health CaremedicineHumans610 Medicine & health030223 otorhinolaryngologyOriginal Paperbusiness.industryHearing TestsComparabilityOutcome measuresAudiogramSensory SystemsClinical trialOssicular Prosthesismedicine.anatomical_structureTreatment OutcomeOtorhinolaryngologyHearing resultsMeta-analysisAustriaMiddle earmedicine.symptombusiness030217 neurology & neurosurgerySwitzerlandAudiologyneuro-otology
researchProduct

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct

Thrombosis and thromboembolism related to COVID‐19: A clarion call for obtaining solid estimates from large‐scale multicenter data

2020

Abstract The clinical spectrum of coronavirus disease 2019 (COVID‐19) is wide, ranging from minor, nonspecific symptoms to severe pneumonia, acute respiratory distress syndrome, multiorgan involvement, and shock. In severe cases, the acute systemic inflammatory response, coagulation activation, and diffuse endothelial damage may, in combination with hypoxia, immobilization, and underlying risk factors, result in potentially life‐threatening venous and arterial thrombotic events. The first data from single‐center retrospective studies suggest that thrombotic events are a key aspect of COVID‐19‐associated morbidity and mortality. We have planned and will be launching the COvid REgistry on THR…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsvenous thromboembolism610 Medicine & healthAcute respiratory distressregistrymedicine.disease_causeSARS‐CoV‐2COVID‐19Internal medicineMedicineIn patientthrombosisCoronavirusCOVIDbusiness.industryForumlcsh:RC633-647.510031 Clinic for AngiologyRetrospective cohort studyHematologylcsh:Diseases of the blood and blood-forming organsHypoxia (medical)medicine.diseaseThrombosismedicine.symptombusinessResearch and Practice in Thrombosis and Haemostasis
researchProduct

European Association of Cardiothoracic Anesthesiology and Intensive Care Pediatric Cardiac Anesthesia Fellowship Curriculum: First Edition.

2022

International audience; Pediatric cardiac anesthesia is a subspecialty of cardiac and pediatric anesthesiology dedicated to the perioperative care of patients with congenital heart disease. Members of the Congenital and Education Subcommittees of the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC) agreed on the necessity to develop an EACTAIC pediatric cardiac anesthesia fellowship curriculum. This manuscript represents a consensus on the composition and the design of the EACTAIC Pediatric Cardiac Anesthesia Fellowship program. This curriculum provides a basis for the training of future pediatric cardiac anesthesiologists by clearly defining the theoretic…

medicine.medical_specialtyCritical Care[SDV]Life Sciences [q-bio]educationMEDLINESubspecialty03 medical and health sciences0302 clinical medicine030202 anesthesiologyPediatric anesthesiologyAnesthesiologyIntensive careAnesthesia Cardiac ProceduresMedicineHumansFellowships and Scholarships610 Medicine & healthChildCurriculumCardiothoracic anesthesiologybusiness.industryGeneral surgery030208 emergency & critical care medicine3. Good healthCardiac AnesthesiaAnesthesiology and Pain MedicinePerioperative carecardiovascular systemCurriculumCardiology and Cardiovascular MedicinebusinessJournal of cardiothoracic and vascular anesthesia
researchProduct

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy :…

2019

Aim To compare clinical characteristics and outcomes in adults with type 1 diabetes aged ≥ 60 years using continuous subcutaneous insulin infusion (CSII) vs. insulin injection therapy. Further, to determine the percentage of older adults with type 1 diabetes using CSII. Research design and methods Retrospective study using data of the Diabetes Prospective Follow-up Registry (DPV). Including percentage CSII use from 2008 to 2018, and the characteristics of 9547 individuals extracted from the DPV in March 2019 (N = 1404 CSII; N = 8143 insulin injection therapy). Wilcoxon rank sum tests were used for continuous variables and chi-square tests for categorical variables to compare clinical charac…

medicine.medical_specialtyDiabetic ketoacidosisEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineDiabetes mellitus Type 1Internal MedicineMedicine030212 general & internal medicineddc:610ContraindicationDepression (differential diagnoses)AgedType 1 diabetesbusiness.industryInsulinCSIIDiabetes mellitus; TherapyDiabetes mellitus Typ 1Retrospective cohort studymedicine.diseaseInsulin infusion systems3. Good healthMicroalbuminuriaOlder peopleInsulinpumpebusinessAlter <60-90 Jahre>
researchProduct

New diagnostic and imaging technologies in dermatology

2021

INTRODUCTION Diagnosis of dermatological disorders is primarily based on clinical examination in combination with histopathology. However, clinical findings alone may not be sufficient for accurate diagnosis and cutaneous biopsies are being associated with morbidity. OBJECTIVE The objective of this article is to review the newer technologies along with their applications, limitation and future prospectus. METHODOLOGY Comprehensive literature search was performed using electronic online databases "PubMed" and "Google Scholar". Articles published in English language were considered for the review. RESULTS In order to improve and/or widen the armamentarium in dermatologic disease diagnosis and…

medicine.medical_specialtyDiagnostic methodsMicroscopy Confocalbusiness.industryEmerging technologies610 MedizinEnglish languageDermatologyDermatologyArtificial Intelligence610 Medical sciencesMedicineHigh frequency ultrasonographyHumansDermatological disordersbusinessTomography Optical CoherenceUltrasonography
researchProduct

WHO needs high FIO2?

2017

World Health Organization and the United States Center for Disease Control have recently recommended the use of 0.8 FIO2 in all adult surgical patients undergoing general anaesthesia, to prevent surgical site infections. This recommendation has arisen several discussions: As a matter of fact, there are numerous studies with different results about the effect of FIO2 on surgical site infection. Moreover, the clinical effects of FIO2 are not limited to infection control. We asked some prominent authors about their comments regarding the recent recommendations.

medicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain Medicine10216 Institute of Anesthesiologybusiness.industryMEDLINE610 Medicine & health030208 emergency & critical care medicineDisease controlWorld health3. Good health03 medical and health sciences0302 clinical medicineAnesthesiology and Pain Medicine030202 anesthesiologySurgical sitemedicineEmergency MedicineInfection controlGeneral anaesthesia2703 Anesthesiology and Pain Medicine2711 Emergency MedicineIntensive care medicinebusinessSurgical site infectionSurgical patients
researchProduct

Current Surgical Treatment Standards for Esophageal and Esophagogastric Junction Cancer

2020

A number of different surgical techniques for the treatment of cancer of the esophagus and the esophagogastric junction have been proposed. Guidelines generally recommend a transthoracic approach for esophageal cancer, including Siewert type I tumors. In tumors of the proximal esophageal third, transthoracic esophagectomy may be extended to a three-field approach, including resection of cervical lymph nodes. However, the choice between transthoracic esophagectomy with intrathoracic anastomosis (Ivor Lewis esophagectomy) and the three-incision approach with cervical esophago-gastrostomy (McKeown esophagectomy) remains controversial, with guidelines varying among different countries. Furtherm…

medicine.medical_specialtyEsophageal Neoplasms610 Medicine & healthGenetics and Molecular BiologyTransthoracic esophagectomyAdenocarcinomaGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineEsophagusHistory and Philosophy of Science1300 General Biochemistry Genetics and Molecular BiologyGastricmedicineHumansEsophagogastric junctionEsophagusNeoplasm MetastasisSurgical treatmentCancer10217 Clinic for Visceral and Transplantation Surgery1207 History and Philosophy of Scienceddc:617business.industryGeneral NeuroscienceAnastomosis SurgicalCancer2800 General NeuroscienceEsophageal cancermedicine.diseaseSurgeryEsophagectomyEsophagogastric junctionmedicine.anatomical_structureCervical lymph nodes030220 oncology & carcinogenesisGeneral BiochemistryAdenocarcinoma030211 gastroenterology & hepatologySurgeryEsophagogastric Junctionbusiness
researchProduct